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Abstract 
High-Throughput (HT) technologies such as miniature bioreactors (MBRs) are 
increasingly employed within the biopharmaceutical manufacturing industry. 
Traditionally, these technologies have been utilized for discrete screening approaches 
during pre-clinical development (e.g. cell line selection and process optimization). 
However, increasing interest is focused towards their use during late clinical phase 
process characterization studies as a scale-down model (SDM) of the cGMP manufacturing 
process. In this review, we describe a systematic approach towards SDM development in 
one of the most widely adopted MBRs, the ambr™ 15 mL and 250 mL (Sartorius Stedim 
Biotech) systems. Recent efforts have shown promise in qualifying ambr™ systems as 
SDMs to support more efficient, robust and safe biomanufacturing processes.  We suggest 
that combinatorial improvements in process understanding (matching of mass transfer 
and cellular stress between scales through computational fluid dynamics and in vitro 
analysis), experimental design (advanced risk assessment and statistical design of 
experiments) and data analysis (combining uni- and multi-variate techniques) will 
ultimately yield ambr™ SDMs applicable for future regulatory submissions. 
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1 Introduction 
The biopharmaceutical industry faces an increasing demand to accelerate the timeline to 
develop commercial cell culture processes. A key regulatory requirement is to 
demonstrate management of product quality control through the identification of critical 
quality attributes (CQAs) and their controlling critical process parameters (CPPs). Such 
process characterization requires the understanding of a multidimensional design space 
in which multiple CPPs can impact CQAs [1]. It is therefore unfeasible to conduct such 
studies at manufacturing scale and representative scale-down models (SDMs) must be 
utilized to adequately interrogate the design space. Traditionally, bench-scale bioreactors 
(BSBs; 1 to 10 L scale) are utilized as upstream SDMs [2-8], however, increasing throughput 
requires the implementation of high-throughput (HT) technologies. 
HT small-scale culture systems such as miniature bioreactors (MBRs), have been widely 
adopted within the industry and are increasingly utilized throughout the lifecycle of a 
biopharmaceutical drug product. Such systems were initially utilized as screening tools 
(e.g. cell line selection and process optimization during early-phase clinical development 
[9-16], but increasing interest is focused towards their use as SDMs of the cGMP 
manufacturing scale processes during late-phase clinical development [17-21]. These 
systems offer the potential to shift the bottleneck away from the resource limitations 
associated with BSBs. However, the application of HT technologies shifts the bottleneck to 
sample and data analysis, which becomes rate limiting, unless effective workflows are in 
place. 
Several competing MBR technologies have been developed, including BioProcessors’ 
SimCell™ microbioreactors [22], microtiter plates [23], Pall’s micro24™ [24], shake flasks [25] 
and spin tubes [26, 27].However, the micro- and mini-scale bioreactor systems ambr15™ 
(10-15 mL working volume) and ambr250™ (100-250 mL working volume) have largely 
become industry standard MBRs [9-21]. 
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The focus of this study is to evaluate the new challenges faced when using ambr™ systems 
as qualified SDMs. One of the very first questions to answer is which SDM criterion to 
select and this is not a trivial answer for a MBR that is geometrically dissimilar to its larger 
scale counterpart. However, the HT data generating capability of ambr™ systems can be 
leveraged to identify the correct SDM criteria for a given cell line/process. Therefore, 
experimental design, data management and data analysis must all be carefully considered. 
With such a modus operandi we can look forward to ambr™ systems providing SDM data 
for future regulatory submissions.  
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2 The importance of SDM criteria  
During the development of a SDM it is important to demonstrate general process 
performance and equivalency of CQAs between small-scale and commercial 
manufacturing scale. Industrial users of the ambr™ system including Biogen [19], BMS [21], 
Genentech [12], KBI [20]. Merck [10, 16, 17], MedImmune [15] and UCB [11, 18] have published their 
observations comparing CQAs between ambr™ systems and BSBs. A brief overview of 
selected important events in the ambr™ timeline can be followed in Figure 1. 
 
 
Figure 1: The ambr™ timeline. A short overview of recent publications using ambr™ 
systems and potential future development around HTPD in SDM.  
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However, ideally cell culture performance at commercial manufacturing scale should be 
used as a baseline to guide SDM development and few examples exist that compare CQAs 
in the ambr™ with manufacturing scale [17-21]. Nevertheless, equivalence to bench-scale 
performance does still provide encouraging baseline data to provide preliminary 
information for SDM development. 
A good SDM needs to not only match commercial manufacturing scale performance but 
also the response of changing process parameters, which can be categorized into scale-
dependent (e.g. working volume, feed volume, agitation, aeration) and scale-independent 
parameters (e.g. pH, dissolved O2/CO2, temperature, media/feed composition, inoculation 
ratios and feed regimes). A general strategy for SDM development is to proportionally 
scale down the scale-dependent parameters whilst maintaining the scale-independent 
parameters at the same set-points used in the manufacturing scale process. However, 
difficulties can occur during the linear scale-down of scale-dependent and the matching of 
scale-independent parameters due to differences in bioreactor geometry, liquid surface-
to-volume ratio, gassing regime and control capability in ambr™ systems.  
Unfortunately, the aforementioned industrial publications on SDM development in ambr™ 
systems do not always detail their SDM criteria (with a few exceptions, which are not 
always peer-reviewed - see Notes and Supplementary Materials). However, available 
information and points to consider when choosing SDM criteria for ambr™ systems are 
detailed below.  
 
 
2.1 Agitation and aeration considerations in the ambr15™ 
One of the most important SDM criteria is the maintenance of mass transfer (O2 supply, 
CO2 stripping and bulk mixing) by agitation and gas sparging. Traditional SDM criteria 
include matching power per unit volume (𝑃/𝑉), tip speed (𝑡𝑠), impeller shear rate (𝛾), 
specific impeller pumping rate (𝑄𝑠), gas flow rate per volume (volume of gas per vessel 
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volume per minute; 𝑣𝑣𝑚), volumetric mass transfer coefficient (𝑘𝐿𝑎)/oxygen transfer rate 
(OTR), and CO2 stripping rate [28-30]. 
Although a limit to gas sparging and agitation exists due to the shear sensitivity of CHO 
cells, it is no longer considered to be a major problem due to the addition of surfactants 
such as Pluronic-F68 to media formulations [31, 32]. Therefore, today critical SDM criteria 
include oxygen transfer, bulk liquid mixing, and dCO2 removal [28-30, 33]. 
It is perhaps unsurprising that the first publications on SDM development in ambr™ 
systems have largely focused on scaling based on traditional engineering parameters, such 
as setting agitation speed through 𝑃/𝑉 or 𝑡𝑠, rather than through detailed experimental 
characterization of oxygen transfer, bulk liquid mixing, and dCO2 removal.  
One of the first peer-reviewed industrial studies of the ambr15™ was Genentech’s 
evaluation of the ambr15™ as a scale-down mimic of their 2 L BSB [12]. Scaling based on 
𝑃/𝑉 and equivalent 𝑣𝑣𝑚 air sparging rate resulted in the most comparable DO profiles 
and culture performance. However, dO2 profiles did take longer to reach the 30% set-point 
in the ambr15™ and spikes occurred in the ambr15™ dO2 profiles, corresponding to 
additions of antifoam/feed and during liquid addition/sampling when O2 is being sparged 
into the vessels as they disturb the head space and alter the working volume. Such 
variation in dO2 may not be a concern for CHO cells which are generally considered 
insensitive to dO2 levels between 10 and 80% [34, 35]. The increased time to reach the 
dO2 set-point may be explained by the observation that agitation rate exerts a higher 
degree of control over kLa in ambr15™ in comparison to larger scale bioreactors [36]. 
This early effort to scale up or down based on 𝑃/𝑉 [12] may have underestimated the 
required agitation rate for matched 𝑃/𝑉. Today’s industrial processes have much higher 
cell concentrations resulting in too low operational RPM to hold dO2, as we have 
experienced with some of our newer cell lines. The 𝑃/𝑉 for an ambr15™ vessel at a given 
𝑡𝑠 is 10-12 fold higher than conventional bioreactors, which is a direct consequence of the 
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different physical characteristics of the ambr15™ and makes it particularly unsuitable for 
this system [36].  
Thus, when considering SDM criteria for the ambr15™ system, 𝑃/𝑉 should not be chosen 
to determine the agitation rate for modern cell culture processes. It is important to note 
that 𝑡𝑠 scaling in ambr15™ systems usually utilizes BSBs at the comparator and this SDM 
criteria may not be appropriate for all bioreactor scales as either the scaled values are not 
practical or 𝑡𝑠 is not the limiting parameter [32, 37, 38], indicating that better SDM metrics 
may have to be established.  
In an article published in 2012 by Hsu at Merck, agitation rates were scaled between the 
ambr15™ (900 rpm) and a 3 L BSB (200 rpm) using a 𝑡𝑠 of 0.5 m/s and a dO2 set point of 
60% [16]. Utilization of a lower agitation speed and higher dO2 set point resulted in 
comparable dO2 profiles between the BSB and the ambr15™ system. The performance of 
two mAb producing cell lines were evaluated in both systems as cell culture performance 
indicators (growth/viability, titer and product quality) were similar in both the BSB and 
the ambr15™.   
In 2014, KBI published a study where the ambr15™ was found to produce matched cell 
culture performance (growth/viability and titer) across scales (3 L, 15 L and 200 L) [20]. 
Importantly, the authors found that the ambr15™ reproduced perturbations in pH, DO2 
and temperature in a similar manner to larger scale systems. Agitation was set to 1,000 
rpm based on a matched 𝑡𝑠 between the ambr15™ system and their 3 L and 15 L BSBs. In 
agreement with the observations of Hsu et al. [12] relatively short (30-60 min) 
perturbations were observed in dO2 during bioreactor sampling and base/feed additions.  
The SDM criteria initially adopted for the ambr15™ by Biogen was that of matching 𝑡𝑠 with 
their 5 L BSB [19]. pCO2 profiles at 15,000L manufacturing scale were replicated in the 
ambr15™ through the introduction of a variable air cap and comparable titer, growth and 
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product quality characteristics were obtained between scales. Furthermore, acceptable 
process parameter ranges were comparable both in the ambr15™ and a 5L BSB. 
A physical characterization study by Nienow et al. [36] utilized a combination of 
experimental and computational methods to report power number, 𝑘𝐿𝑎 and mixing time 
for ambr15™ vessels . Whereas the flow regime in a 5L BSB was found to be essentially 
turbulent, the flow regime in the ambr15™ was found to be transitional. The authors 
hypothesized that matched culture performance across scales may be due to a balance 
between fluid mechanical stress (agitation and bursting bubbles) and environmental 
heterogeneity (nutrients, pH, dO2, dCO2 or osmolality). Stress in the ambr15™ may be 
focused more towards fluid mechanical stress and environmental heterogeneity may be 
more of a concern at increased scale.  
Currently, decomposing the exact contribution of stresses to poor process 
performance/cell death with analytical tools is challenging. There is a lower priority to 
measure stress signals compared to established metabolic markers. Even if stresses are 
measured in subpopulations, the root cause for apoptosis, lysis or necrosis may not be 
entirely clear. A similar stress level should be established by carefully selecting 
appropriate parameters during scaling up/down, which adequately represent process 
performance at commercial scale.  
 
2.2 Agitation and aeration considerations in the ambr250™ 
ambr250™ vessels are more geometrically similar to larger-scale systems than the 
ambr15™. This theoretically enables key engineering assumptions (e.g. consistent power 
input) to be applied and result in maintenance of similar fluid dynamics and flow 
properties.  
One of the first peer-reviewed industrial studies of the ambr250™ was Merck’s evaluation 
of the ambr250™ as a SDM of a 3L BSB and a 200L bioreactor. 𝑃/𝑉 was utilized as a SDM 
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criteria and two CHO cell lines were shown to reach comparable cell culture performance 
(cell growth/viability, titer) [10]. Data on comparable mAb quality for one cell line was also 
reported. The same group also reported utilizing the same SDM criteria (𝑃/𝑉) to reach 
comparable cell growth/viability, metabolic profiles, titer and product quality for a CHO 
cell line at ambr250™, 3 L, 650 L and 2,500L scales [17]. Interestingly, pCO2 profiles were 
shown to be different across the different scales utilized.  
In 2017, BMS published a paper on SDM criteria selection in the ambr250™ [21]. In this 
study, SDM criteria including 𝑣𝑣𝑚, 𝑃/𝑉, and 𝑘𝐿𝑎 were assessed using different CHO cell 
lines and cell culture performance between the ambr250™, 5 L BSBs, 250L and 1,000 L 
scales was evaluated. The ambr250™ was found to require higher 𝑣𝑣𝑚 flow rates to 
achieve the same 𝑘𝐿𝑎 at matched 𝑃/𝑉 to larger scale systems. The authors hypothesized 
that this was due to the difference in sparger design between the ambr250™ (open pipe) 
and either drilled hole or drilled hole and frit spargers utilized in larger scale systems.  
The 𝑘𝐿𝑎 values obtained (2 – 14 h-1) were comparable to those obtained by Bareither et al.  
(2.5 – 8.5 h-1) [10]. The 𝑘𝐿𝑎 values reported for the ambr15™ are between 2.1 and 12.97 h-1 
[36] and the 𝑘𝐿𝑎 values of the ambr250™ are slightly lower than those reported for the 
ambr15™ at the same 𝑣𝑣𝑚. When 𝑘𝐿𝑎 was utilized by BMS as a SDM criteria for cell line A, 
ambr250™ growth profiles and titer matched with those of 5 L and 250 L bioreactors. For 
cell line B, the cell growth of the ambr250™ matched those of 5 L, 250 L, and 1000 L 
bioreactors with 2 day delay in peak cell density and the titer of the ambr250™ varied ~ 
5% from that obtained at larger scale. A further, six CHO cell lines were compared in the 
ambr250™ and in a 5L BSB. The cell growth characteristics of three clones matched those 
of the BSB and the other three clones had slightly different peak cell densities or growth 
profiles at the later stage of culture. Using 𝑘𝐿𝑎 as SDM criterion may be appropriate for 
cell screening activities and applicable for the majority of CHO cell lines. Further fine-
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tuning and the application of other SDM criteria (e.g. pCO2) may allow the ambr250™ to 
become a better SDM mimic of large-scale bioreactors.  
 
2.3 Temperature considerations in ambr™ systems 
Each of the ambr15™ culture station blocks of 12-vessels can be maintained at different 
temperatures and most studies report robust temperature control. However, temperature 
control in the ambr15™ can be influenced by the environmental temperature [12] and care 
should be taken to maintain ambient conditions (21 – 25 ∘C) as per the manufacturer’s 
recommendations. In comparison, each ambr250™ vessel can be maintained at different 
temperatures and temperature is controlled in a similar manner to larger scale vessels 
with a liquid filled temperature control jacket. 
 
2.4 pH control considerations in ambr™ systems 
One of the disadvantages of the first generation of pH optical sensors utilized in MBRs was 
the loss of sensitivity to pH over time, leading to the inability of these vessels to control pH 
later in culture [23, 39]. However, the pH optical sensors utilized in ambr15™ systems have 
largely been shown to robustly measure pH throughout a production run.  
pH control in the ambr15™ is achieved by bolus addition of base and by CO2 sparging. The 
amount of base to add is determined empirically by equating the volume of base required 
to change the pH of the cell culture media by one unit [20]. Adjustments to this “base scale 
factor” may be needed during the production process due to altered media gas state, 
media composition and altered buffering capacity. Another consideration is the minimum 
volume threshold of the ambr15™ liquid handler (10 µL), as for some processes a weaker 
base than the larger scale process may need to be utilized to control pH [12]. Overshoots in 
pH control have also been reported in ambr15™ systems that correlate to the addition of a 
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basic feed [20]. Such pH drifts can be controlled through tuning CO2 gas flow limits and the 
proportional gain in the PI loop.  
The ambr250™ utilizes a gel electrode single-use probe which are similar to the probe 
electrodes typically used in larger-scale systems. Moreover, pH control in the ambr250™ 
utilizes PID regulator settings in a similar way to larger-scale vessels.  
 
2.5 Feeding and sampling considerations 
Both the ambr15™ and ambr250™ system can be integrated with automated cell culture 
analyzers including the NovaBioProfile FLEX2, Beckman Coulter ViCELL XR, Cedex HiRes 
and ambr™ pH analysis module to allow collection of cell culture data including total and 
viable cell density, viability, cell diameter, pH, dCO2, dO2, glucose, lactate, glutamine, 
glutamate, ammonium, Na+, K+, Ca+ and osmolality. However, careful attention needs to 
be paid to the sample volume required for such systems (typically 600 µL), especially 
when conducting daily sampling in small volume (10 to 15 mL) ambr15™ systems.   
Indeed, typically volume increases through fed-batch culture duration in larger scale 
system whereas the volume in ambr15™ systems can decrease due to sampling 
requirements. This can have a detrimental effect on cell culture performance as lower 
volumes leads to increased gas sparging, which causes aberrant foaming and aggravates 
dO2 set-point control. Furthermore, it can take up to 3 hours to analyze all 48 vessels of an 
ambr15™ system which results in a tradeoff between data quantity and experimental 
throughput.  
An article by Rowland-Jones et al., [40] compared different spectroscopic technologies (NIR, 
Raman and 2D-Fluorescence) to try and resolve this bottleneck. Constraints were imposed 
so that all analytes were measured in less than one hour and the sample volume was less 
than 50 µL. Whereas 2D-Fluorescence was the most suitable technology to quantify 
ammonium concentration, Raman spectroscopy was the most robust technology for 
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lactate and glucose concentration and was therefore implemented as the at-line platform 
technology.  
Furthermore, once a day sampling may not be appropriate to mimic processes which 
utilize advanced process analytical technologies that rely on online measurements of cell 
growth and metabolism [41]. Nevertheless, Goldrick et al., [42] recently published an 
example of advanced process control in ambr15™, 7 L and 50 L bioreactors by controlling 
glucose concentration through online measurement of oxygen transfer rate. 
The higher 𝑣𝑣𝑚 gas flow rates required in ambr systems can lead to aberrant foam 
generation which requires additional bolus antifoam additions for adequate control. 
Increased antifoam additions may impact cell culture performance parameters [43] and can 
create difficulties in downstream processing [44]. 
Furthermore, only the front set of vessels can be assessed visually for their foam level. 
Therefore, users typically feed all vessels with antifoam if foam is apparent in the front set 
of vessels. An interesting observation by Velugula-Yellela et al. [43] was that as foaming 
increased, so did the frequency of variability in the dO2 measurements. Therefore, 
variability in dO2 profile may serve as a potential tool in developing foam control strategy 
and we recommend antifoam addition when dO2 variability is high. Both the ambr15™ and 
ambr250™ can be utilized to add stepwise feed additions, although only the ambr250™ 
has integrated pumps allowing continuous feed additions. To date, fed-batch processes 
remain the predominantly reported procedure ran in ambr™ system and the authors are 
not aware of any published state-of-the-art intensified high cell density processes of > 50 x 
106 viable cells/mL. At this time no commercially available cell separation devices can be 
integrated with the ambr15™ and the utilization of open pipe spargers in both ambr™ 
systems may provide the required 𝑘𝐿𝑎 for typical fed-batch processes, but this may 
become limiting for intensified high cell density processes. Nevertheless, Kelly et al. [45] 
have recently published an example of a semi-continuous ambr15™ model, which matched 
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metabolic shifts and specific metabolic and protein production rates for a 5 L perfusion 
process. However, the maximum viable cell density of this process was relatively low (~ 
20 x 106 viable cells/mL). The recent announcement of an ambr250™ HT perfusion vessel 
holds great promise for the future. These vessels are fitted with a multi-hole sparger and 
integrated cell separation device making them more amenable to intensified high cell 
density processes.  
 
3 Removing the bottleneck in experimental design and data analysis with the 
application of advanced statistical tools 
Even with the application of HT technologies such as the ambr™, not all process 
parameters can be investigated and it is important to generate as much process 
knowledge as possible with as few experiments as necessary. The first step towards 
mapping the process design space is to identify process parameters and to assess the risk 
of each to process robustness. Typically, a formal risk assessment exercise such as Failure 
Modes and Effect Analysis (FMEA) is conducted to identify factors that could influence 
CQAs and reduce the number of possible process parameters [2, 5]. Previous process 
knowledge can play a key role in this process [2, 5, 19].  Indeed, Janakiraman et al. [19] 
acknowledged the importance of prior process knowledge during the development of 
their ambr15™ SDM of a 15,000 L fed-batch process. 
The overwhelming amount of data generated in HT systems calls for efficient 
experimental design, data handling and data analysis platforms. Traditional strategies for 
experimental design rely on the variation of one factor at a time which is laborious, time-
consuming and does not account for synergistic interactions between components. 
Therefore, Design of Experiments (DoE) is an indispensable tool that facilitates the 
analysis of a large number of variables simultaneously and helps identify their 
interactions [2, 5, 46-49]. 
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The volume of data generated in HT systems can be overwhelming and efficient in silico 
data handling platforms are needed to streamline data entry, processing and access 
requirements. Multivariate data analysis (MVDA) techniques can then be helpful to 
summarize data in a meaningful fashion. 
Researchers at Biogen utilized MVDA as a qualification tool to develop an ambr15™ scale 
down model that showed comparability with both manufacturing scale and bench scale 
[19]. Similar MVDA methodology had also been used previously by Biogen to improve a 
bench scale bioreactor model to match the manufacturing scale process [6, 7]. Despite the 
qualification of the scale down model using MVDA the authors noted the importance of 
applying prior process knowledge (in the form of wet lab characterization experiments), 
to ensure critical process parameters are closely aligned across different scales [19].  
Goldrick et al. [50] demonstrated that a combination of DoE studies and MVDA (MLR and 
PLS-R) can be used to identify and predict product quality heterogeneity (trisulphide bond 
formation) in ambr15™ and 7 L BSBs. 
A word of caution is advised when making SDM claims from multivariate summary 
parameters, such as principal components. While it may be true that principal components 
easily enable comparisons between datasets, some variables must also be explored 
individually with classical univariate data analysis (UVDA). In other words; data 
summarized in a new, reduced variable space of two or more principal components may 
appear to match well, but this does not mean that CPPs or CQAs are also matched. It is 
clear that UVDA alone does not reveal any interactions and therefore both techniques 
should be utilized [51, 52]. 
The assessment of any SDM’s equivalence requires statistical interrogation techniques 
which aim to compare individual variables and their equivalence or lack thereof. An 
example is the two one-sided test (TOST), which can be utilized to make a statement about 
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equivalence or non-equivalence of variables. Genzyme have presented a time-series TOST 
approach for SDM qualification of a micro-carrier perfusion cell culture [53]. 
FUJIFILM Diosynth Biotechnologies have reported the importance of both UVDA 
(statistical process control (SPC), t-test, F-test, Mann-Whitney Test etc.) and MVDA 
techniques (PCA, PLS, variable importance in projection (VIP), Hotelling’s confidence 
ellipsoids etc.), their roles in validation, and provide the reader with a list of items to 
consider when qualifying a process in different scales [51]. 
An example of the utilization of multivariate tools to gain further process understanding 
during cell culture process development has been provided by Sokolov et al., [54] who 
utilized a sequential procedure to derive the required information to define further 
experimentation and decide on the appropriate experimental scale.  
In summary, the incorporation of statistical techniques and multivariate modeling tools 
are indispensible tools that support the analysis of HT experiments and establishment of 
SDM in major pharmaceutical companies today, of which some few are mentioned in 
Figure 2. 
 
Figure 2: Frequently used data analysis tools in industry. PCA (Principal Component 
Analysis), PLS-R (Partial Least Squares Regression, T² (Hotelling’s Square), RSP (Response 
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Surface Plots), SPC (Statistical Process Control), Equivalence Testing (TOST, tolerance 
intervals).  
4 Reaching qualified SDM status with ambr™ systems and their role in accelerating 
process characterization/validation studies 
To reach qualified SDM status, ambr™ process CQAs should match those at the commercial 
scale and any differences should be well understood. Qualification process robustness can 
be reinforced by the utilization of media and feed stocks that have been used in 
commercial scale manufacturing batches.  A well-characterized system is crucial for 
obtaining regulatory approval as can be seen in the example of the first QbD submission 
by Genentech’s Perjeta where this was initially not the case [Kim S., QbD in Biologics: 
Genentech’s success and failure in design space approval, QbD Works, 2013, accessed Dec 
2017, <http://qbdworks.com/qbd-biologics-genentechs-success-failure-design-space-
approval/>].  
Regulatory authorities welcome submissions which are supported by DoEs coming from 
small scales such as the discussed ambr™ systems. When they are set up to represent a 
large scale process as closely as possible, these physical models may identify CQAs and the 
criticalities of process parameters. This may improve process knowledge and help to 
devise a control strategy to manage residual risk presented by individual or a combination 
of process parameters (Text box).  
  
 19 
Text box  
Text box 1: Regulatory perspectives 
Excerpt from the EC’s GMP Annex 15: 
Process validation should establish whether all quality attributes and process parameters, which are 
considered important for ensuring the validated state and acceptable product quality, can be consistently 
met by the process. The basis by which process parameters and quality attributes were identified as being 
critical or non-critical should be clearly documented, taking into account the results of any risk assessment 
activities. For all products irrespective of the approach used, process knowledge from development studies 
or other sources should be accessible to the manufacturing site, unless otherwise justified, and be the basis 
for validation activities. 
A much more formal approach for qualification and validation of a process to manufacture medicinal 
products for human and veterinary use can be found in the FDA’s Guidelines for Industry Process 
Validation: General Principles and Practices1 and in the EC’s (European Commission) Guidelines to Good 
Manufacture Practice (EU GMP, EudraLex, Volume 4 and Annexes2). The topic of process validation may not 
be discussed in the required depth in this format, some aspects relevant for the purposes of this 
contribution, namely how SDM studies can be used as part of a process validation strategy, are highlighted 
here. The EC’s GMP Annex 15 (Sections 5.7., 5.10) can be consulted for more information on small scale 
studies, which support and form the basis of validation activities for licensed products2. Following these 
guidelines with quality risk based principles, the number of full scale process validation batches may be 
potentially decreased. It is well recognized that for clinical phase material, the requirements for formal 
process validation are low with the exception of viral clearance for some processes. This offers 
opportunities to improve a medicinal product while still under investigation, e.g. for clinical trials. It also 
implies that well-designed SDM studies can be used to set in-process controls for manufacture already in 
small scale, see EU GMP Annex 13 (Section 16. & 17)2.  
1 FDA, Guidance for industry. Process Validation: General Priniciples and Practices, FDA, 2011, accessed 
Dec 2017, <https://www.fda.gov/downloads/Drugs/Guidances/UCM070336.pdf>. 
2 European Commission, EudraLex – Volume 4 – Good Manufacturing Practice (GMP_ guidelines, European 
Commission, 2010, accessed Dec 2017, <https://ec.europa.eu/health/documents/eudralex/vol-4_en>. 
 
An important consideration when utilizing ambr™ systems as SDMs is that ultimately 
different SDM criteria may be operated for different scales but these variations must not 
significantly impact CQAs. Furthermore, the criticality of certain process parameters may 
vary on a cell line and process specific basis and conflicts may occur between CPPs. For 
example, a balance between agitation and sparging must be found to supply sufficient 
oxygenation without cellular stress. Ultimately, the smart selection of SDM criteria should 
be based on a prioritization of process parameters which most impact CQAs for a given 
cell line and process. (Figure 3). 
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Figure 3: Selection of critical process parameters in ambr™ systems. A ‘”sweet spot” 
of process parameters, in which all scale-down mode criteria are matched, may be 
unattainable. In practice, scale down model criteria are in conflict with each other, 
however, some exert greater control of critical quality attributes (CQAs) than others and 
these drive the selection of critical process parameters (CPPs).  
 
Furthermore, what if a large number of process parameters are deemed equally critical 
and the design criteria cannot be met in a manageable number of experiments?  Even if a 
SDM does not demonstrate equivalence in every single CPP or CQA, it is still possible to 
address the importance of certain parameters with partial (or sometime worst-case) SDMs 
 [McKnight N., Scale-down model qualification and use in process characterization. CMC 
Strategy Forum, 2013, accessed Dec 2017, 
<c.ymcdn.com/sites/www.casss.org/resource/resmgr/CMC_No_Am_Jan_Spkr_Slds/2013_
CMCJ_McKnightNathan.pdf>]. Such SDMs can be used to investigate particular subsections 
of experimental ranges and can be utilized for provocation studies e.g. effect of pCO2 
profiles, shear stress, or physico-chemical gradients on cell metabolism, viability and 
productivity [55].  
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Ultimately, rather than having a ‘one size fits all SDM’ for process characterization and 
validation studies, ambr™ systems may play a role as partial SDMs that allow more 
targeted studies of the direction and magnitude of particular effects. Regardless of 
whether ambr™ systems are utilized as fully miniaturized SDMs or as partial SDMs, both 
require qualification.  
Data from a SDM alone would not be accepted instead of commercial scale process 
validation, as its role is presumed to support and not to replace process validation 
activities. This qualified status can only be attained once clinical phase manufacturing data 
becomes available. However, if the quality of the data is high and a high level of process 
knowledge can be demonstrated, the SDM may be expected to reduce the burden of full 
scale validation and support certain claims instead. These claims could be e.g. proven 
acceptable ranges or they may permit reduction of number of batches executed for 
process qualification purposes (PPQ). A checklist of questions and answers was prepared 
to guide researchers in justifying how they developed und justified their SDM (Table 1). 
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Table 1: Checklist to prepare for regulatory SDM justification. This checklist 
intentionally does not cover all aspects of SDM, rather it should be a helpful summary of 
questions and their answers that were agglomerated from various sources over the course 
of this study. 
 
Question Answer 
How should scale-
dependent and 
scale-
independent 
parameters be 
selected in the 
SDM? 
Scale-independent parameters such as pH, pO2, temperature, nutrient feed addition 
schedule, seed density and others should be operated at the set-point conditions of large 
scale to qualify the SDM [18]. 
 
Scale-dependent engineering parameters such as agitation, aeration, vessel pressure, 
working volume, residence times, geometric similarity, nutrient feed volume, gas 
stripping and cell physiology should be comparable in the SDM to ensure comparable 
performance with large scale [13]. 
How can 
equivalence of the 
SDM be 
demonstrated? 
Equivalence is expected to be demonstrated by overlaying time profiles of variables such 
as viable cell density, culture viability, bioreactor titer and others. Metabolic markers 
such as pCO2 or specific consumption rate profiles may be included. Those QAs selected 
for equivalence estimation should be impacted in similar ways both in large scale and in 
the SDM, otherwise the SDM may not be representative enough for the overall process 
[67]. 
Which QAs should 
be compared in 
the SDM? 
Critical QAs may be known beforehand for a specific product, in which case they have to 
be included in the SDM comparison. In case they are not known, identification of product 
related QAs can be driven by those which are known to be influenced by this stage and 
also by knowledge of the impact in DSP. Frequently, QAs for comparison of small scale 
and commercial scale are: titre, purity, aggregates, fragments, charge variants and glycan 
profile [55][68]. 
How could 
comparability of 
QAs be 
demonstrated in 
the SDM?  
Compare QA time profiles or end points. Acceptance criteria for comparability in the 
SDM should not be as strict as if the drug was submitted as a commercial end product. If 
a small proportion of a large number of QA’s identified for the purpose of comparison 
are demonstrated to have not scaled particularly well, this would not necessarily 
invalidate the SDM. Instead, it could be shown that some QAs are scale-dependent and 
which process parameter caused the offset. A justification is appropriate, for instance 
when conditions were selected that would compromise less important QAs but keep 
most CQAs within an acceptable range [53]. 
When can I use a 
Design Space 
from my SDM? 
A Design Space validation would not end after a singular validation run, instead the DS 
will be challenged with data on a regular basis for ongoing confirmation. Any process 
adjustments made at full commercial scale as part of routine manufacture would have to 
be validated by the SDM in terms of the outputs measured at both scales. Regulatory 
authorities would anticipate the DS to be adequately and continuously monitored and 
verified as part of the DS qualification at commercial scale during normal lifecycle. These 
verifications serve to further qualify the SDM [FDA, Guidance for industry. Process 
Validation: General Priniciples and Practices, FDA, 2011, accessed Dec 2017, 
<https://www.fda.gov/downloads/Drugs/Guidances/UCM070336.pdf>].  
 
 
Many biopharmaceutical companies employ platform processes that are designed to 
accelerate the timeline to clinical manufacturing [56]. These encompass a combination of 
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well-tested components, such as cell line, media/feed strategies, equipment configuration 
and scale-up strategy. Ideally, the majority of processes would fit to the qualified platform 
process and both ambr™ systems already fit very well into the platform concept as a 
widely utilized screening tool. Therefore qualified ambr™ could be utilized to start process 
characterization studies much earlier (during cell line selection and process optimization) 
and speed up the development life-cycle of today’s drug manufacturing process. 
 
5  Increasing understanding of the culture environment at small and large scale 
An important pre-requisite for a SDM is that the cell culture environment is matched as 
closely as possible between small and large scale. This understanding requires a detailed 
evaluation of both mass transfer (O2 supply, dCO2 stripping and bulk mixing) and cellular 
stress at each scale. 
Detailed process knowledge and extensive in vitro characterization of process equipment 
through the establishment of predictive models and simulation tools based on 
fundamental engineering principals are necessary to determine matched cell culture 
performance between scales [57]. Computational fluid dynamics (CFD) can also be utilized 
to provide an in silico visualization of flow patterns, local gradients and shear sensitive 
zones [32, 36, 58, 59]. Once visualized, mass transfer and stress heterogeneity between scales 
can be matched [60].  
Of interest in the future will be how best to leverage the information provided by –OMICS 
technologies to help understand the differences in the cellular environment between 
scales. An example of such an approach has been published by BMS in which a combined 
metabolomics and proteomic approach identified hypoxia as the cause for differences in 
process performance differences between a 20 L BSB and a 5,000 L bioreactor [61]. Another 
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recent example by Alsayyari et al., [62] observed only small differences in overall gene 
expression between ambr15™ and 10L BSB systems. 
Furthermore, whereas classical scale-down criteria include the matching of process set-
points such as dO2, a more elegant approach may involve setting a lower dO2 set-point at 
the small-scale (homogenous mixing environment) to match the average CFD 
derived/cellular stress at the heterogeneous large-scale (heterogeneous mixing 
environment) [63]. This may be a very process specific recommendation, as some cell lines 
are more sensitive to the same stresses than others. Nevertheless, we believe that 
properly selecting and reproducing large scale stresses in small scale, either by 
appropriate physical or computational tools [64, 65, 66], will improve our understanding and 
result in more robust commercial processes.  
 
6 Conclusions 
MBRs such as the ambr™ systems are powerful tools for the biopharmaceutical 
manufacturing industry. However, regardless of their success and rapid adaptation, they 
are still often viewed as complementary screening platforms rather than SDMs of 
commercial scale manufacturing processes. The question therefore remains, how can 
these systems transition into SDMs? 
One challenge that researchers face is that SDM criteria may not be 1:1 comparable 
between small- and large-scale. Therefore, these novel MBRs require extensive 
characterization and also novel SDM criteria to match CQAs across scales. However, even 
traditional methods of SDM qualification utilizing BSBs can be challenging and the HT 
capability of ambr™ systems enables rapid exploration of the multivariate design space. 
Therefore, key to the adoption of ambr™ systems will be the application of advanced risk 
analysis and statistical tools such as FMEA, DoE, UVDA, and MVDA to remove bottlenecks 
in experimental design and data analysis.  
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It is important to note that not all processes may be applicable to utilizing ambr™ systems 
as “one-stop shop” SDMs and it is important to fully understand equipment limitations and 
the relevant CPPs and CQAs that are to be matched. ambr™ systems may therefore play a 
role as partial SDMs that allow more targeted studies of the direction and magnitude of 
particular effects in BSBs. Nevertheless, evidence is already available that suggests that 
ambr™ systems can be utilized to represent certain aspects of manufacturing scale 
processes. Further process understanding and data generated for HT SDMs should further 
expand their utility and reduce the resource requirements and time-line for process 
characterization and validation studies. With this outlook we can look forward to the first 
regulatory submissions utilizing ambr™ SDMs that are expected to showcase the best 
practice in some, if not all disciplines (Figure 4). 
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Figure 4: Expected evolution of ambr™ utilization over time. The biopharmaceutical 
industry already widely utilizes the ambr™ as a screening platform. Challenges today are 
development and validation of scale down models for cGMP manufacturing processes. HT 
data will require automation and adequate database tools that allow uni- and multivariate 
statistical analysis. Finally, the innovators of our time will have to demonstrate that the 
cumulative quality of all work elements leads to a positive regulatory submission, which 
will firmly establish the ambr™ as an integral element of biopharmaceutical drug 
development. 
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Notes 
This review contains a supplement table with typical operational setpoints for ambr™ 
systems in mammalian cell culture and a few notes on the experiments.   
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